INTELLIA THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
INTELLIA THERAPEUTICS, INC. (NTLA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.85 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-01.
Discontinued › Cash Flow
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-01
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$1.85M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$2.40M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$2.26M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$1.27M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$10.09M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$6.17M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$2.55M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 8 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$1.85M 10-Q · filed 2018-05-01 | -$4.25M derived: sum of 2 quarters · filed 2018-05-01 | -$6.51M derived: sum of 3 quarters · filed 2018-05-01 | -$7.78M derived: sum of 4 quarters · filed 2018-05-01 | |
| 2017-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$4.66M derived: sum of 2 quarters · filed 2018-03-14 | -$5.93M derived: sum of 3 quarters · filed 2018-03-14 | -$10.09M 10-K · filed 2018-03-14 | |
| 2017-09-30 | -$2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | -$3.53M derived: sum of 2 quarters · filed 2017-10-31 | -$7.69M 10-Q · filed 2017-10-31 | -$11.10M derived: sum of 4 quarters · filed 2018-05-01 | |
| 2017-06-30 | -$1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$5.43M 10-Q · filed 2017-08-01 | -$8.84M derived: sum of 3 quarters · filed 2018-05-01 | -$9.44M derived: sum of 4 quarters · filed 2018-05-01 | |
| 2017-03-31 | -$4.16M 10-Q · filed 2018-05-01 | -$7.57M derived: sum of 2 quarters · filed 2018-05-01 | -$8.17M derived: sum of 3 quarters · filed 2018-05-01 | -$9.32M derived: sum of 4 quarters · filed 2018-05-01 | |
| 2016-12-31 | -$3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$4.01M derived: sum of 2 quarters · filed 2018-03-14 | -$5.16M derived: sum of 3 quarters · filed 2018-03-14 | -$6.17M 10-K · filed 2018-03-14 | |
| 2016-09-30 | -$605.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | -$1.75M derived: sum of 2 quarters · filed 2017-10-31 | -$2.76M 10-Q · filed 2017-10-31 | -$3.61M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-06-30 | -$1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | -$2.15M 10-Q · filed 2017-08-01 | -$3.00M derived: sum of 3 quarters · filed 2018-03-14 | -$3.61M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-03-31 | -$1.01M 10-Q · filed 2017-05-02 | -$1.86M derived: sum of 2 quarters · filed 2018-03-14 | -$2.46M derived: sum of 3 quarters · filed 2018-03-14 | -$3.05M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2015-12-31 | -$849.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$1.45M derived: sum of 2 quarters · filed 2018-03-14 | -$2.04M derived: sum of 3 quarters · filed 2018-03-14 | -$2.55M 10-K · filed 2018-03-14 | |
| 2015-09-30 | -$602.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | -$1.19M derived: sum of 2 quarters · filed 2016-11-01 | -$1.71M 10-Q · filed 2016-11-01 | ||
| 2015-06-30 | -$587.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$1.10M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$516.00K 10-Q · filed 2016-06-03 | ||||
| 2014-12-31 | -$575.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |